Tislelizumab and anlotinib for thymus cancer after first treatment
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of two drugs (tislelizumab and anlotinib) as a second treatment option for people with thymoma or thymic carcinoma whose cancer has worsened after first-line therapy. It aims to see if this combination can control the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with thymoma or thymic carcinoma.
- Your cancer got worse during or after your first treatment (chemotherapy with or without immunotherapy).
- You have not taken anlotinib or similar anti-angiogenesis drugs before.
- You do not have an active autoimmune disease.
- Your heart, liver, kidney, and blood counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the immunotherapy drug adebrelimab with chemoradiation before surgery can help shrink locally advanced thymic carcinoma and improve outcomes. It is for people who have not yet received treatment for their thymic carcinoma.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a combination of two drugs (tislelizumab and anlotinib) for people with advanced lung cancer whose first immunotherapy treatment stopped working. The goal is to see if this new combination can help when the first treatment stopped being effective.
This study tests a combination of three treatments—an immunotherapy drug called tislelizumab, chemotherapy, and a procedure called BACE—for advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs, anlotinib (a targeted therapy) and benmelstobart (an immunotherapy), for people with differentiated thyroid cancer that has spread or cannot be removed. It may be an option if your cancer did not respond to or got worse after first treatment.
Hear when a new Thymic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.